Abstract 1961P
Background
Sarcomas are rare malignant tumors and represent a heterogeneous group of tumors. An accurate diagnosis of histology is important for treatment strategies. We assessed the pathological review of all patients diagnosed with sarcoma at Siriraj Hospital over a 5-year period to identify the number of first diagnoses compared to the central expert review.
Methods
Histological data from patients diagnosed with sarcoma at Siriraj Hospital were collected over a 5-year period. The initial diagnoses were compared with a certified soft tissue and bone tumor pathologist.
Results
Of the 185 selected patients, 107 (57%) met the inclusion criteria and were analyzed. Full concordance between primary diagnosis and second opinion (the first pathologist and expert reached identical conclusions) was observed in 35 (32.7%) cases, partial concordance (identical diagnosis of connective tumor but different grade or histological type) in 12 (11.2%) cases, and complete discordance (benign versus malignant, different histological type, or invalidation of the diagnosis of sarcoma) in 60 (56.1%) cases. The rate of discordance was higher in incomplete initial IHC (p = 0.003), private laboratory, grade 2 and 3, tumor size ≥ 100 mm (p = 0.01) and age >18. The most common 'full concordance' histology is osteosarcoma (100%, 4 of 4). The main discrepancies were related to histological type (n = 60, 56.1%), subtype (n = 8, 7.5%), and grade plus subtype (n = 4, 3.7%). The mean duration from diagnosis to treatment was 96 days. Only the complete initial report appeared different in the subgroup <97 days group 39 (73.6%) and 97 days group 14 (26.4%) (p=0.03).
Conclusions
More than 65% of the first histological diagnoses were modified in the second reading, possibly resulting in different treatment decisions. The second opinion of the expert improves the quality of diagnosis and possibly the treatment of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1830P - CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study
Presenter: Kaiwen Li
Session: Poster session 15
1831P - Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?
Presenter: Lisa Horvath
Session: Poster session 15
1832P - Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort
Presenter: Javier Freire
Session: Poster session 15
1833P - Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Presenter: Channing Paller
Session: Poster session 15
1834P - Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15
1835P - A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
Presenter: Shahneen Sandhu
Session: Poster session 15
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Presenter: Maria Ruiz Vico
Session: Poster session 15
1837P - Assessing PSA
Presenter: Susan Halabi
Session: Poster session 15
1839P - Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
Presenter: George Seed
Session: Poster session 15